

Order for Felix™ System to Evaluate Suitability in UAE

Australian biotechnology company Memphasys Limited (ASX: MEM) (Memphasys or the Company) is pleased to announce the receipt of an order for its Felix™ System from a clinic in Dubai, United Arab Emirates (UAE). The order includes one demonstration unit and 30 cartridges and is intended to evaluate the system's suitability for research use only under the Ministry of Health and Prevention (MOHAP) guidelines. The order is facilitated by Panacea Medizintech LLC, a distributor of laboratory and medical products based at Sharjah Media City in the UAE.

The order represents an important initial step in determining the viability of the Felix™ System within the UAE's regulatory framework. Notably, medical devices in the UAE must comply with regulations set by the MOHAP. To adhere to these regulations, the Felix™ System has been supplied on a "For Research Use Only", with no claims made regarding its suitability for clinical use or distribution. This approach ensures compliance with MOHAP regulations while allowing for rigorous evaluation by key opinion leaders.

Strategic Importance of the UAE Market

The UAE represents a strategic market for Memphasys, given its role as a regional hub for advanced medical technologies and its emphasis on innovation in assisted reproductive technology. The outcomes of this evaluation will inform Memphasys' strategy for expanding into the Middle Eastern market and determining pathways for regulatory compliance and adoption of the Felix™ System.

The in vitro fertilisation (IVF) market in the Middle East, particularly in the United Arab Emirates (UAE), is experiencing significant growth, driven by rising infertility rates, advancements in medical technology, and the region's emergence as a hub for medical tourism.

The Middle East and Africa (MEA) IVF market is forecast to reach USD 3 Billion by 2033, with a CAGR of 11.99%.¹

UAE's Role in Medical Tourism

Dubai has established itself as a premier destination for medical tourism, attracting a significant number of international patients seeking various treatments, including in vitro fertilisation (IVF). In 2022, the emirate welcomed approximately 674,000 medical tourists, with this number increasing to over 691,000 in 2023.²

While specific data on the exact number of tourists traveling to Dubai exclusively for IVF procedures is not readily available, fertility treatments are among the sought-after services. In 2022, fertility

¹ <https://www.sperresearch.com/report-store/mea-in-vitro-fertilization-market.aspx?>

² <https://mediaoffice.ae/en/news/2024/august/19-08/dubai-welcomes-more-than-691k?>

treatments were among the specialties that attracted medical tourists from Asia, Europe, and Africa, including GCC and Arab countries.³

Additionally, leading clinics in Dubai report that approximately 10% of their patients are overseas tourists seeking fertility treatments.

Commenting on the order, Memphasys CEO and Managing Director, Dr David Ali, said:

“This order underscores the growing interest in the Felix™ System and its potential to meet the needs of key opinion leaders and clinics globally. We are excited to explore the system’s applicability in the UAE and look forward to feedback from this important evaluation process.”

Next Steps

Memphasys will work closely with Panacea Medizintech LLC during the evaluation process, providing support and guidance to ensure optimal outcomes. Insights from this initiative will contribute to Memphasys’ ongoing efforts to expand the Felix™ System’s global footprint, including obtaining regulatory clearances such as the CE Mark and TGA certification.

Memphasys remains committed to advancing the development and commercialisation of the Felix™ System in compliance with all applicable regulatory standards.

About the Felix™ System

The Felix™ System is a patented, automated device for separating high-quality sperm for use in human artificial reproduction. The system is designed to improve sperm selection processes with speed, precision, and reduced oxidative stress, making it a significant innovation in assisted reproductive technology.

This announcement has been approved for release by the Board of Memphasys Limited.

ENDS

For further information, please contact:

Dr David Ali
Managing Director & CEO
Memphasys Limited
Tel: +61 2 8415 7300
E: david.ali@memphasys.com

David Tasker
Managing Director
Chapter One Advisors
Tel: +61 433 112 936
E: dtasker@chapteroneadvisors.com.au

³ <https://mediaoffice.ae/en/news/2023/april/12-04/dubai-medical-tourists?>

About Memphasys

Memphasys Limited (ASX: MEM) specialises in reproductive biotechnology for high value commercial applications. Reproductive biotechnology products in development include medical devices, in vitro diagnostics, and new proprietary media. The Company's patented bio separation technology, utilised by the Company's most advanced product, the Felix™ System, combines electrophoresis with proprietary size exclusion membranes to separate the most viable sperm cells for human artificial reproduction.

Website: www.memphasys.com

The Felix™ System is a registered trademark of Memphasys Limited. All rights reserved.

For personal use only